Hyperfine (HYPR) Resumen de Acciones
Hyperfine, Inc. es una empresa de tecnología sanitaria dedicada a la producción, suministro, servicio y comercialización de productos de imagen por resonancia magnética (IRM). Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 1/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
HYPR Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Hyperfine, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$1.30 |
| Máximo en las últimas 52 semanas | US$2.22 |
| Mínimo de 52 semanas | US$0.76 |
| Beta | 1.4 |
| Cambio en 1 mes | -5.80% |
| Variación en 3 meses | 17.12% |
| Cambio de 1 año | 69.93% |
| Variación en 3 años | -38.10% |
| Variación en 5 años | -86.91% |
| Variación desde la OPV | -87.01% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 18
HYPR: Emergency Imaging Adoption And Europe Approvals Will Support Stock Upside
Analysts have maintained their $2.00 price target on Hyperfine, making only minor adjustments to underlying assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support a stable valuation view. What's in the News for Hyperfine Hyperfine presented results from the PRIME trial at the Society for Academic Emergency Medicine 2026 Annual Meeting, reporting that bedside use of the Swoop portable MRI system in neurological emergencies was associated with a median imaging wait time of 1.28 hours compared with 7.76 hours for conventional MRI, and that portable MRI detected critical brain pathology that was later confirmed on standard MRI.
Actualización de narrativa • Jun 04
HYPR: Expanded Global Access To Portable MRI Will Drive Future Upside
Analysts have lifted their price target on Hyperfine from $2.00 to $2.50, citing updated assumptions for revenue growth, profit margins, and future P/E that contribute to a slightly higher fair value estimate and discount rate. What's in the News Hyperfine reaffirmed full year 2026 revenue guidance of approximately US$20 million to US$22 million, with management indicating this would represent 55% growth at the midpoint compared with 2025.Actualización de narrativa • May 20
HYPR: European Regulatory Wins And New Loan Facility Will Support Upside
Analysts have raised their price target for Hyperfine from $1.60 to $2.00, reflecting updated assumptions regarding discount rates, revenue growth, profit margins, and future price-to-earnings (P/E) expectations. What's in the News Reaffirmed full year 2026 revenue guidance of approximately US$20 million to US$22 million, with management indicating this implies 55% growth at the midpoint compared with 2025 (company guidance).Recent updates
Actualización de narrativa • Jun 18
HYPR: Emergency Imaging Adoption And Europe Approvals Will Support Stock Upside
Analysts have maintained their $2.00 price target on Hyperfine, making only minor adjustments to underlying assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support a stable valuation view. What's in the News for Hyperfine Hyperfine presented results from the PRIME trial at the Society for Academic Emergency Medicine 2026 Annual Meeting, reporting that bedside use of the Swoop portable MRI system in neurological emergencies was associated with a median imaging wait time of 1.28 hours compared with 7.76 hours for conventional MRI, and that portable MRI detected critical brain pathology that was later confirmed on standard MRI.Actualización de narrativa • Jun 04
HYPR: Expanded Global Access To Portable MRI Will Drive Future Upside
Analysts have lifted their price target on Hyperfine from $2.00 to $2.50, citing updated assumptions for revenue growth, profit margins, and future P/E that contribute to a slightly higher fair value estimate and discount rate. What's in the News Hyperfine reaffirmed full year 2026 revenue guidance of approximately US$20 million to US$22 million, with management indicating this would represent 55% growth at the midpoint compared with 2025.Actualización de narrativa • May 20
HYPR: European Regulatory Wins And New Loan Facility Will Support Upside
Analysts have raised their price target for Hyperfine from $1.60 to $2.00, reflecting updated assumptions regarding discount rates, revenue growth, profit margins, and future price-to-earnings (P/E) expectations. What's in the News Reaffirmed full year 2026 revenue guidance of approximately US$20 million to US$22 million, with management indicating this implies 55% growth at the midpoint compared with 2025 (company guidance).Artículo de análisis • May 15
Hyperfine, Inc. (NASDAQ:HYPR) Analysts Are Pretty Bullish On The Stock After Recent Results
Hyperfine, Inc. ( NASDAQ:HYPR ) just released its quarterly report and things are looking bullish. Revenues were better...Actualización de narrativa • Apr 30
HYPR: European Approvals And New Financing Will Support Future Upside Potential
Analysts have raised their price target on Hyperfine by $0.30, citing updated fair value assumptions of $1.60 per share that reflect adjusted expectations for revenue growth, profit margins, discount rate, and a higher future P/E multiple. What's in the News Received CE Marking and UK Conformity Assessment approval for the next generation Swoop portable MRI system and the latest Optive AI software, allowing commercialization across Europe and the UK.
Actualización de narrativa • Apr 16
HYPR: European Approvals And Clinical Evidence Will Drive Future Upside
Analysts now set a $2.05 price target for Hyperfine, unchanged from before, reflecting updated views on discount rate, profit margin, and expected future P/E, without a shift in the overall valuation level. What's in the News Hyperfine received CE Marking and UKCA approval for its next generation Swoop system and latest Optive AI software, clearing the way for commercialization of its portable MRI technology across Europe and the UK and broadening its international reach in brain imaging (Product related announcement).Actualización de narrativa • Apr 01
HYPR: Growing Clinical Evidence In Stroke And Outpatient Care Will Drive Upside
Analysts have lifted their Hyperfine price target from $1.65 to $2.05, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that adjust the stock's risk and earnings outlook in their models. What’s in the News Entered a new loan and security agreement with Horizon Technology Finance Corporation for a senior secured term loan facility of up to US$40 million, including an initial US$15 million draw and the option to access an additional US$25 million through December 31, 2027, with interest only payments through March 18, 2031 (Key Developments).Actualización de narrativa • Mar 18
HYPR: Expanding Stroke And Outpatient Evidence Will Support Future Upside
Analysts have maintained their $1.65 price target for Hyperfine, citing largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for this view. What's in the News The largest data set to date for stroke detection with the Swoop system reported strong evidence supporting AI powered portable MRI for ischemic stroke detection in emergency and other clinical settings.Actualización de narrativa • Mar 04
HYPR: Expanding Clinical Evidence And New Trials Will Support Future Upside
Analysts have kept their price target for Hyperfine steady at $1.65, with small tweaks to assumptions such as a slightly higher discount rate, modestly better projected profit margin, and a somewhat lower future P/E helping to support the unchanged view. What's in the News The largest stroke detection data set to date for the Swoop system was reported.Actualización de narrativa • Feb 18
HYPR: India Approval And Clinical Data Will Support Future Upside Potential
Analysts have modestly revised their price target for Hyperfine to $1.30, reflecting updated assumptions around a slightly lower discount rate, marginally higher revenue growth and profit margin expectations, and a small adjustment to the projected future P/E multiple. What's in the News The largest stroke detection data set for the Swoop system was published in Stroke: Vascular and Interventional Neurology.Actualización de narrativa • Feb 04
HYPR: Growing Clinical Evidence And New Approvals Will Support Upside
Analysts have kept their price target for Hyperfine unchanged at $1.65, reflecting only minor adjustments to underlying model inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The largest-to-date stroke detection study with the Swoop system reported strong sensitivity and specificity for ischemic lesion detection, including very small strokes, with shorter scan times and improved brain image quality in emergency settings (Stroke: Vascular and Interventional Neurology).Actualización de narrativa • Jan 21
HYPR: Expanded Clinical Use And New Regulatory Wins Will Drive Upside
Analysts have modestly adjusted their price target for Hyperfine to US$1.65, reflecting tweaks to key inputs such as a slightly lower discount rate, marginally softer revenue growth and profit margin assumptions, and a higher future P/E expectation. What's in the News Hyperfine enrolled the first patient in the Contrast PMR study, a prospective multi center trial evaluating contrast enhanced ultra low field portable MRI to support a potential future FDA submission to expand Swoop system use with gadolinium based contrast agents.Artículo de análisis • Jan 15
Revenues Tell The Story For Hyperfine, Inc. (NASDAQ:HYPR) As Its Stock Soars 34%
Hyperfine, Inc. ( NASDAQ:HYPR ) shareholders are no doubt pleased to see that the share price has bounced 34% in the...Actualización de narrativa • Jan 06
HYPR: India Approval Will Support Future Upside Potential
Analysts have modestly adjusted their price target on Hyperfine, reflecting small tweaks to the discount rate, revenue growth and future P/E assumptions while keeping fair value steady at US$1.30. What's in the News Hyperfine received regulatory approval in India for its Swoop portable MRI system from the Central Drugs Standard Control Organization, allowing commercialization across the country through a distribution partnership with Radiosurgery Global Ltd.Actualización de narrativa • Dec 18
HYPR: India Approval And New MRI Software Will Drive Strong Upside Potential
Analysts have raised their price target on Hyperfine from approximately $0.85 to $1.30 per share, citing stronger projected revenue growth, slightly improved profit margins, and a higher expected future P E multiple, despite a modest uptick in the assumed discount rate. What's in the News Hyperfine received regulatory approval from India's Central Drugs Standard Control Organization to commercialize its Swoop portable MRI system nationally, opening access to advanced brain imaging in a large, under-served market (Key Developments).Actualización de narrativa • Dec 04
HYPR: Expanded Clinical Use And Subscription Platform Will Drive Future Upside
Analysts have maintained their price target for Hyperfine at 1.65 dollars, reflecting largely unchanged views on the company. Slight improvements in discount rate and profit margin estimates are offset by a marginally lower future earnings multiple.Actualización de narrativa • Nov 20
HYPR: Expanding Clinical Applications Will Drive 2025 Revenue Acceleration
Narrative Update on Hyperfine: Analyst Price Target Revision Analysts have slightly reduced their price target for Hyperfine from $1.70 to $1.65, citing updated forecasts for revenue growth and profit margins as key factors behind the adjustment. What's in the News Management expects fourth quarter 2025 revenue to be approximately $5 to $6 million, which would represent sequential and year-over-year quarterly growth of 60% and 137%, respectively.Actualización de narrativa • Nov 05
HYPR: International Approvals And Expanded Use Will Drive Upside Momentum
Narrative Update on Hyperfine Analyst Price Target Analysts have maintained their fair value estimate for Hyperfine at $1.70. They cite largely unchanged growth projections along with only small adjustments in profit margin and discount rate assumptions.Actualización de narrativa • Oct 21
Analysts Lift Hyperfine Price Target Amid Positive Studies and Stronger Revenue Growth Forecast
Analysts have raised their price target for Hyperfine from $1.42 to $1.70. They cite higher projected revenue growth and a slightly lower discount rate as reasons for a more bullish outlook.Artículo de análisis • Oct 07
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 30% Price Jump
Despite an already strong run, Hyperfine, Inc. ( NASDAQ:HYPR ) shares have been powering on, with a gain of 30% in the...Actualización de narrativa • Aug 29
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
The significant upward revision in Hyperfine’s consensus analyst price target is primarily driven by a notable increase in its forecasted Future P/E, with fair value rising from $1.19 to $1.42. What's in the News Hyperfine provided 2025 earnings guidance, expecting 10%–20% revenue growth over 2024.Actualización de narrativa • Aug 15
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
With both Net Profit Margin and Future P/E essentially unchanged, analysts have maintained their consensus price target for Hyperfine at $1.19. What's in the News Hyperfine received FDA clearance for its next-generation portable MRI system powered by Optive AI software, delivering significant improvements in image quality, speed, and usability, targeting broader adoption across diverse care settings, including hospitals, neurology offices, and remote environments.Artículo de análisis • Jul 23
Market Participants Recognise Hyperfine, Inc.'s (NASDAQ:HYPR) Revenues Pushing Shares 46% Higher
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a really impressive month, gaining 46% after a shaky period beforehand...Artículo de análisis • May 16
Here's Why Hyperfine (NASDAQ:HYPR) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Nueva narrativa • Apr 09
2025 Swoop Software Releases Will Boost Healthcare Imaging Adoption
Launching AI-powered software and expanding into neurology offices will likely enhance market penetration and diversify revenue streams.Artículo de análisis • Mar 22
What You Can Learn From Hyperfine, Inc.'s (NASDAQ:HYPR) P/S After Its 28% Share Price Crash
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a horrible month, losing 28% after a relatively good period beforehand...Artículo de análisis • Feb 05
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 25% Price Jump
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have continued their recent momentum with a 25% gain in the last month alone...Artículo de análisis • Nov 15
Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results
Shareholders might have noticed that Hyperfine, Inc. ( NASDAQ:HYPR ) filed its third-quarter result this time last...Rentabilidad de los accionistas
| HYPR | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | -9.7% | 2.2% | 1.6% |
| 1Y | 69.9% | -19.0% | 18.6% |
Rentabilidad vs. Industria: HYPR superó a la industria US Medical Equipment, que obtuvo un rendimiento del -19% el año pasado.
Rentabilidad vs. Mercado: HYPR superó al mercado US, que obtuvo un rendimiento del 18.6% el año pasado.
Volatilidad de los precios
| HYPR volatility | |
|---|---|
| HYPR Average Weekly Movement | 12.4% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: El precio de las acciones de HYPR ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de HYPR(12%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2014 | 102 | Maria Degois-Sainz | www.hyperfinemri.com |
Hyperfine, Inc, empresa de tecnología sanitaria, se dedica a la producción, suministro, servicio y comercialización de productos de imagen por resonancia magnética (IRM). Su sistema portátil de IRM Swoop produce imágenes con una intensidad de campo magnético inferior a la de los escáneres de IRM convencionales. La empresa también ofrece servicios de soporte y asistencia técnica, así como Hyperfine Image Viewer, un sistema de comunicación y archivo de imágenes en la nube.
Resumen de fundamentos de Hyperfine, Inc.
| Estadísticas fundamentales de HYPR | |
|---|---|
| Capitalización bursátil | US$129.05m |
| Beneficios(TTM) | -US$34.78m |
| Ingresos (TTM) | US$15.33m |
8.4x
Ratio precio-ventas (PS)-3.7x
Ratio precio-beneficio (PE)¿Está HYPR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de HYPR | |
|---|---|
| Ingresos | US$15.33m |
| Coste de los ingresos | US$7.48m |
| Beneficio bruto | US$7.85m |
| Otros gastos | US$42.63m |
| Beneficios | -US$34.78m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.35 |
| Margen bruto | 51.20% |
| Margen de beneficio neto | -226.88% |
| Ratio deuda/patrimonio | 38.2% |
¿Cómo se ha desempeñado HYPR a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/06 16:20 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Hyperfine, Inc. está cubierta por 4 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Vijay Kumar | Evercore ISI |